Melanotan-2 (MT-2) Research: What Published Studies Have Investigated

What is Melanotan-2?

What is Melanotan-2? It is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH), also written MT-2 or MT-II. In the literature it is characterized as a non-selective (pan-)melanocortin-receptor agonist, with activity described across the melanocortin receptor family (MC1R–MC5R). It was developed out of α-melanotropin structure-activity work at the University of Arizona (Al-Obeidi, Hadley, Hruby and colleagues, late 1980s). That is a neutral molecular definition of what the compound is and how it was characterized as a melanocortin-receptor ligand; the sections below describe what researchers examined, not effects in people.

Molecule properties

Melanotan-2 is a cyclic heptapeptide. Its defining structural feature is a lactam (Asp-Lys) bridge that constrains the peptide backbone into a conformationally restricted ring, a design change reported to confer greater metabolic stability than the flexible linear α-MSH analogs it descended from (Al-Obeidi et al. 1989). The design lineage runs from linear α-melanotropin analogs to this constrained cyclic form, and the cyclisation is what the medicinal-chemistry papers credit for the peptide’s prolonged activity in assays: the ring locks the pharmacophore into an active-like conformation rather than leaving it free to unfold. Melanocortin peptides share a conserved central His-Phe-Arg-Trp message sequence, and the α-melanotropin analog work that produced MT-2 was built around preserving and rigidifying that core recognition motif — a neutral chemistry fact about melanocortin structure-activity, not a statement about any effect.

In research catalogues MT-2 is supplied as a lyophilized powder, which is why it is listed as a research peptide rather than a formulated product. It is also worth drawing the endogenous-ligand versus synthetic-analog distinction plainly: α-MSH is the natural melanocortin ligand released from proopiomelanocortin (POMC) processing, while MT-2 is a synthetic research analog modelled on it and studied for its receptor pharmacology. These are molecule facts only — no handling or reconstitution instructions, and the sequence is not offered as a recipe.

Mechanisms researchers have examined

The Melanotan-2 mechanism literature centres on melanocortin-receptor pharmacology. Each direction below is framed as what researchers examined, in cell and animal models, not as an effect in a reader:

• Non-selective melanocortin-receptor agonism — MT-2 was characterized as binding and activating multiple melanocortin receptor subtypes across the MC1R–MC5R family, which distinguishes it from subtype-selective analogs. This is framed strictly as receptor pharmacology.
• Melanogenesis signaling in melanocyte models — MC1R activation and downstream cAMP-linked eumelanin-synthesis pathways were examined in classic melanotropin bioassays, including frog and lizard skin assays and mammalian melanoma tyrosinase assays; Al-Obeidi et al. (1989) reported high potency relative to native α-MSH. This is described as a research mechanism only — a receptor-and-cell-signaling observation, not a cosmetic effect.
• Structure-activity and conformational design — the cyclic scaffold was designed with quenched molecular-dynamics simulations, and the resulting constrained peptide showed prolonged, potent activity in melanotropin assays (Al-Obeidi et al. 1989). This is medicinal-chemistry design work.
• Central melanocortin signaling (MC3R/MC4R) context — the broader melanocortin-4 pathway is a recognized research target in the receptor family. A separate melanocortin agonist, bremelanotide (PT-141), was later developed and studied independently (Molinoff et al. 2003). This is receptor-family context only, and not a claim about what MT-2 does.

Taken together, the compound has been characterized primarily in receptor-pharmacology and cell- and animal-model assays. Each bullet names a pathway that was examined in a model system, not an effect that a reader would experience.

Research history and models in the literature

The foundational record is medicinal-chemistry and receptor-pharmacology work from the University of Arizona program (Al-Obeidi, Castrucci, Hadley, Hruby 1989), which designed the constrained cyclic α-melanotropin scaffold and reported its potency and prolonged activity in melanotropin bioassays. On the human side there is one early small pilot: Dorr et al. (1996, Life Sciences, PMID 8637402) described a single-blind, placebo-controlled pilot-phase study in a small number of volunteers and documented adverse effects, including nausea and flushing, as part of that early evaluation. That is reported here as a historical research record — it is not guidance, and it is not a statement of outcomes a reader should expect. The honest overall picture is limited: the compound is offered strictly for research use, it is not an approved therapeutic, and human interventional data are confined to small early studies. It should also be kept distinct from the separately developed, separately approved melanocortin agonist bremelanotide — the two are different molecules with different development histories and should not be conflated.

The research models behind these citations are worth naming, because they define what the evidence can and cannot support. The foundational data come from receptor and cell assays and classic amphibian and mammalian melanotropin bioassays, which measure pharmacology in isolated systems rather than outcomes in people. The single early human record is a small pilot-phase evaluation, not a large controlled trial. Read accurately, that means the literature establishes MT-2 as a potent, non-selective melanocortin-receptor agonist in model systems and records early-phase observations in a small group of volunteers — it does not establish approved therapeutic use, and animal or in-vitro findings cannot be extrapolated to human outcomes. That limitation is the honest frame for everything on this page.

Documented safety-signal literature

A separate strand of the literature documents safety signals, and it is included here neutrally because it is part of the honest research record. Published case reports and reviews have described signals associated with the use of unlicensed melanotropic peptides, including changing or atypical melanocytic nevi and melanoma reports (Langan et al. 2010, Br J Dermatol; Hjuler & Lorentzen 2014, Dermatology), and at least one report of systemic toxicity with rhabdomyolysis (Nelson et al. 2012, Clin Toxicol, PMID 23121206). These are presented strictly as documented literature findings — not as advice, not as risk-management instruction, and not as a scare piece. They are noted plainly because they are exactly why this compound is catalogued for laboratory research use only and handled with per-batch Certificate-of-Analysis identity verification rather than treated as a consumer product.

Melanotan-2 in the melanocortin-peptide research group

In one line: MT-2’s defining research arm is non-selective melanocortin-receptor agonism, which is what sets it apart from subtype-selective analogs and from separately developed agonists such as bremelanotide. It sits within the broader melanocortin and receptor-signaling research area alongside other signaling peptides studied for their defined receptor targets — for a related receptor-targeting signaling-peptide explainer, see Kisspeptin research, and for another short signaling peptide characterized around a specific receptor pathway, see KPV research. This page deliberately hands off to those sibling pages rather than rebuilding their detail, and it keeps its own scope to what the Melanotan-2 literature investigated.

Research-grade sourcing and verification

For laboratory research use only, Melanotan-2 is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is sourcing, identity and quality-assurance framing only, not a statement about outcomes.

Frequently asked questions

Literature cited

1. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. “Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics.” Journal of Medicinal Chemistry. 1989;32(12):2555-61. Companion: Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. “Design of a New Class of Superpotent Cyclic α-Melanotropins Based on Quenched Dynamic Simulations.” J. Am. Chem. Soc. 1989;111:3413-3416.
2. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sciences. 1996;58(20):1777-84. PMID 8637402.
3. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Annals of the New York Academy of Sciences. 2003;994:96-102. PMID 12851303.
4. Langan EA, Nie Z, Rhodes LE. “Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’?” British Journal of Dermatology. 2010;163(3):451-5.
5. Nelson ME, Bryant SM, Aks SE. “Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.” Clinical Toxicology. 2012;50(10):1169-73. PMID 23121206.
6. Hjuler KF, Lorentzen HF. “Melanoma associated with the use of melanotan-II.” Dermatology. 2014;228(1):34-6.